Good news on the cancer front.
-
Apparently it’s available now, for $689. Got this email today.
Cancerguard logo
Stay proactive. Take your next step in cancer screening with Cancerguard
You already know the value of screening with Cologuard
.
Did you know there is an innovative new test that complements standard screening?
Meet the Cancerguard test, from the makers of Cologuard
Most cancers — about 70% — don’t have routine screening options.1 That’s where Cancerguard can make a difference. This simple blood test helps detect:50+ cancer types and subtypes with one blood draw1
Aggressive, hard-to-find cancers, including liver, lung, ovarian, and pancreatic, even at early stages
Even before symptoms appear, when cancer is easier to treat
Learn about the test
How do I get it?
Icon
Request the test online
Request the Cancerguard test through our telehealth provider partner
Icon
Talk to your providerGet a Cancerguard prescription through
your health care provider
It’s $689, HSA/FSA eligible, and includes additional support if you have a positive result.*- If you have a positive result, you'll get personalized support from a Care Navigator (a nurse or other health professional), and you may be eligible for reimbursement of non-covered imaging costs up to $6,000 through our Imaging Reimbursement Program. Patients must apply. Eligibility depends on program qualifications, which are subject to change) and is not guaranteed. The program will not reimburse any covered imaging costs, including copay, coinsurance, and/or deductible amounts determined by insurance. For more information patients should contact to apply, call 1-844-870-8870 .
Data on file. Cancerguard Test development study. 2025. Bioinformatics, Exact Sciences, Madison, WI.
Exact Sciences logo
Exact Sciences Laboratories, LLC
1 Exact Lane
Madison, WI 53711
Part of the laboratories of Exact Sciences
Cologuard, Cancerguard, and Exact Sciences are registered trademarks of Exact Sciences Corporation.
2025 Exact Sciences Corporation. All rights reserved.
Important Information about the Cancerguard Test:
Rx only. Talk to your healthcare provider to determine if this test is right for you.
The Cancerguard
test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant. Results should be interpreted in the context of a patient’s medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (18F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV- contrast) may be appropriate in the context of the patient’s medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.
Please do not reply, as this email address cannot accept replies.
If you wish to contact Exact Sciences Corporation, please click here.
This message is intended only for individuals in the United States.
Exact Sciences respects your privacy. Please click here to view our Privacy Policy.
For more information about Cancerguard, visit Cancerguard.com.
This advertisement was sent to you by Exact Sciences.
About Exact Sciences
Unsubscribe from all future emails - If you have a positive result, you'll get personalized support from a Care Navigator (a nurse or other health professional), and you may be eligible for reimbursement of non-covered imaging costs up to $6,000 through our Imaging Reimbursement Program. Patients must apply. Eligibility depends on program qualifications, which are subject to change) and is not guaranteed. The program will not reimburse any covered imaging costs, including copay, coinsurance, and/or deductible amounts determined by insurance. For more information patients should contact to apply, call 1-844-870-8870 .
